Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

PureTech Health PLC (PRTC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow PureTech Health's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
28.50 +0.62    +2.22%
26/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 500
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 26.77 - 28.50
PureTech Health 28.50 +0.62 +2.22%

PureTech Health PLC Company Profile

 
Get an in-depth profile of PureTech Health PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

96

Equity Type

DRC

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Contact Information

Address 6 Tide Street Suite 400
Boston, 02210
United States
Phone 617 482 2333
Fax 617 482 3337

Top Executives

Name Age Since Title
Kevin Flaherty - 2021 Member of Clinical Advisory Board
Marlies Wijsenbeek - 2021 Member of Clinical Advisory Board
Kiran Mazumdar-Shaw 70 2020 Independent Non-Executive Director
Williamson Z. Bradford 61 2021 Member of Clinical Advisory Board
Toby Maher - 2021 Member of Clinical Advisory Board
Vincent Cottin - 2021 Member of Clinical Advisory Board
Paul W. Noble - 2021 Member of Clinical Advisory Board
Raju S. Kucherlapati 80 2014 Interim Chair & Senior Independent Director
James J. Collins 57 2015 Advisor
R. Rox Anderson 73 2016 Advisor
Rakesh K. Jain 74 - Advisor
Daphne Bavelier - - Advisor
James Oakley Hill - - Advisor
Ruslan Medzhitov - - Advisor
Helen Christensen - 2016 Advisor
Lee M. Kaplan - - Advisor
Daniel R. Littman 71 - Advisor
Dennis Arthur Ausiello 79 2015 Board Advisor
Caroline M. Apovian - - Advisor
Kenya Honda - - Advisor
Joseph C. Kvedar - - Advisor
Ken Fujioka - 2016 Advisor
Ralph Weissleder - 2016 Advisor
Bharatt M. Chowrira 59 2017 CEO & Executive Director
Robert J. Perez 60 2016 Senior Advisor
David A. Edwards 63 2016 Advisor
Stephen V. Faraone - 2016 Advisor
Jeffrey M. Karp - 2016 Advisor
Edward S. Boyden - 2016 Advisor
Steven H. Holtzman 70 2016 Advisor
Louis J. Aronne 68 2016 Advisor
Donald E. Ingber - 2016 Senior Advisor
Alexander Rudensky - - Advisor
Arne V. Astrup - - Advisor
Alberto Recordati 71 - Advisor
Allan Geliebter - - Advisor
Martin J. Blaser - 2016 Advisor
Howard B. Rosen 66 - Advisor
Aimee Danielson - 2016 Advisor
Maria Gloria Dominguez-Bello - 2016 Advisor
Bennett M. Shapiro 84 2020 Board Advisor
Geraldine Dawson - 2016 Advisor
Frederick Frank 92 - Senior Advisor
Maurizio Fava - - Advisor
Jeff Conn - - Advisor
B. Brett Finlay - - Advisor
Colin R. Gardner - - Advisor
Adam Gazzaley 54 - Advisor
Robert Zatorre - - Advisor
H. Robert Horvitz - 2015 Board Observer
Scott H. Kollins - 2016 Advisor
Tristan Jehan - - Advisor
Derrick J. Rossi - 2016 Advisor
Michael B. Brenner - 2016 Advisor
Rob Knight - 2016 Advisor
Ulrich H. von Andrian-Werburg - 2016 Advisor
Ian Gotlib - 2016 Advisor
Mark S. George - - Advisor
Samir Mitragotri - - Advisor
Robert M. Post - - Advisor
George Cotsarelis - - Advisor
Julien Epps - 2016 Advisor
Siddhartha Mukherjee 53 2016 Advisor
Sam Kass - 2016 Advisor
Alan Breier - 2016 Advisor
Joseph W. St. Geme - 2016 Advisor
Feng Zhang - 2016 Advisor
Philip Just Larsen - 2016 Senior Advisor
Angelo Tremblay - 2016 Advisor
Robert T. Schultz - 2016 Advisor
John L. LaMattina 74 2009 Independent Non-Executive Director
Daphne Zohar 53 2015 Senior Advisor & Board Observer
David R. Elmaleh 76 - Co-Founder & Senior Advisor
Robert S. Langer 75 2015 Co-Founder & Non-Executive Director
Sharon Barber-Lui 50 2022 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PRTC Comments

Write your thoughts about PureTech Health PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email